Review Article
Research Trends and Hotspots in Levodopa-induced Dyskinesia: A Bibliometric Analysis (2015-2024)
Haixin Shi
,
Jiaxuan Chen,
Xinman Fan,
Xiaoxin Xu,
Xiaohong Xu*
Issue:
Volume 11, Issue 1, March 2026
Pages:
1-13
Received:
25 January 2026
Accepted:
12 February 2026
Published:
27 February 2026
Abstract: Levodopa is a core therapeutic agent for Parkinson's disease (PD), while its long-term administration often leads to levodopa-induced dyskinesia (LID), which significantly compromises patients’ quality of life. This study utilizes bibliometric analysis to examine research trends in LID over the past decade, with the aim of identifying key research hotspots and prospective directions in the field. Relevant publications published between 2015 and 2024 were retrieved from the Web of Science and PubMed databases. A total of 691 articles were ultimately included for systematic analysis. Visual analytic techniques were applied using VOSviewer and CiteSpace to examine publication trends, contributions by countries and institutions, author collaboration networks, and keyword clustering. The annual number of publications in LID research exhibited a declining trend over the study period, with a peak in 2015. The United States and institution CNRS (Centre National de la Recherche Scientifique) contributed most significantly. Movement Disorders was the leading journal in both publication volume (54 articles) and citations (2,369). Author Huot P. was the most prolific (25 articles). Keyword analysis identified core themes encompassing "disease-drug-complication-intervention-model." The knowledge structure developed around key clusters: disease models and Parkinson Disease/Drug Therapy. Trend analysis revealed a move from retrospective etiology to refined safety assessments and mechanism-driven interventions. This study outlines the global research landscape and developmental trends in LID, thereby providing a theoretical foundation for future investigations into non-invasive brain stimulation, precision medicine, and novel drug therapies. Further research should emphasize early LID prediction, targeted treatments, and multidisciplinary management.
Abstract: Levodopa is a core therapeutic agent for Parkinson's disease (PD), while its long-term administration often leads to levodopa-induced dyskinesia (LID), which significantly compromises patients’ quality of life. This study utilizes bibliometric analysis to examine research trends in LID over the past decade, with the aim of identifying key research ...
Show More
